Zhang et al., 2014 - Google Patents
Enhanced cellular entry and efficacy of tat conjugates by rational design of the auxiliary segmentZhang et al., 2014
View HTML- Document ID
- 14125167524869286793
- Author
- Zhang P
- Lock L
- Cheetham A
- Cui H
- Publication year
- Publication venue
- Molecular pharmaceutics
External Links
Snippet
Conjugation with a cell penetrating peptide such as Tat presents an effective approach to improve the intracellular accumulation of molecules with low membrane permeability. This strategy, however, leads to a reduced cellular entry of molecules that can cross cell …
- 230000001413 cellular 0 title abstract description 38
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48238—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
- A61K47/48246—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
- A61K47/48792—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a colloid, emulsion, i.e. having at least a dispersed/continuous oil phase and a dispersed/continuous aqueous phase, dispersion or suspension
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48169—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule
- A61K47/48192—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule the organic macromolecular compound has been obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas, polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48007—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent
- A61K47/48023—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | Enhanced cellular entry and efficacy of tat conjugates by rational design of the auxiliary segment | |
Zhang et al. | Cellular uptake and cytotoxicity of drug–peptide conjugates regulated by conjugation site | |
Qian et al. | Discovery and mechanism of highly efficient cyclic cell-penetrating peptides | |
Albertazzi et al. | Dendrimer internalization and intracellular trafficking in living cells | |
Zhou et al. | The role of cell‐penetrating peptides in potential anti‐cancer therapy | |
Suma et al. | Modulated fragmentation of proapoptotic peptide nanoparticles regulates cytotoxicity | |
Li et al. | Self-assembly of amphiphilic peptides for recognizing high furin-expressing cancer cells | |
Sanchez-Navarro et al. | Jumping hurdles: Peptides able to overcome biological barriers | |
Traboulsi et al. | Macrocyclic cell penetrating peptides: A study of structure-penetration properties | |
Boeneman et al. | Selecting improved peptidyl motifs for cytosolic delivery of disparate protein and nanoparticle materials | |
Shi et al. | A survey on “Trojan Horse” peptides: opportunities, issues and controlled entry to “Troy” | |
Mekuria et al. | IL-6 antibody and RGD peptide conjugated poly (amidoamine) dendrimer for targeted drug delivery of HeLa cells | |
Xiang et al. | Enhancing siRNA-based cancer therapy using a new pH-responsive activatable cell-penetrating peptide-modified liposomal system | |
Zhou et al. | Taurine boosts cellular uptake of small D-peptides for enzyme-instructed intracellular molecular self-assembly | |
Anajafi et al. | Nuclear localizing peptide-conjugated, redox-sensitive polymersomes for delivering curcumin and doxorubicin to pancreatic cancer microtumors | |
Albertazzi et al. | Delivery and subcellular targeting of dendrimer-based fluorescent pH sensors in living cells | |
Alhakamy et al. | Polyarginine molecular weight determines transfection efficiency of calcium condensed complexes | |
Sigg et al. | Stimuli-responsive codelivery of oligonucleotides and drugs by self-assembled peptide nanoparticles | |
Zhu et al. | Penetratin derivative-based nanocomplexes for enhanced intestinal insulin delivery | |
Karagiannis et al. | Rational design of a biomimetic cell penetrating peptide library | |
Veneti et al. | RGD-targeted liposome binding and uptake on breast cancer cells is dependent on elastin linker secondary structure | |
Kumar et al. | Peptide self-assembled nanocarriers for cancer drug delivery | |
Chang et al. | Effect of cationic cyclopeptides on transdermal and transmembrane delivery of insulin | |
Yamada et al. | Chirality switching within an anionic cell-penetrating peptide inhibits translocation without affecting preferential entry | |
Cryan et al. | Increased intracellular targeting to airway cells using octaarginine-coated liposomes: in vitro assessment of their suitability for inhalation |